CIPLA MEDPRO SOUTH AFRICA LIMITED - 2012 ANTIRETROVIRAL TENDER RESULTS

2012 ANTIRETROVIRAL TENDER RESULTS

CIPLA MEDPRO SOUTH AFRICA LIMITED
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
(ISIN Number: ZAE000128179 Share Code: CMP)
("Cipla Medpro" or "the Group" or “the Company”)

2012 ANTIRETROVIRAL TENDER RESULTS


Cipla Medpro is pleased to announce the results of the South African HP13-2013 Antiretroviral
(“ARV”) Tender (“the Tender”) as released by the South African Department of Health yesterday.
The Group has been successful in securing the largest portion of the Tender which runs from 1
January 2013 to 31 December 2014 with a total award of approximately R1.448 billion. This is a
significant improvement of more than 120% on our previous ARV tender which was valued at
R633 million from 2010 to 2012. The Company’s allocation represents approximately 25% of the
Tender.

With this Tender and the previously awarded respiratory tender, tender business between the
Government and Cipla Medpro should exceed R2 billion for the next two years.

30 November 2012
Bellville
Sponsor
Nedbank Capital

Date: 30/11/2012 03:17:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.